Latest news with #EdwardWoo
Yahoo
2 days ago
- Business
- Yahoo
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares. This adjustment follows the company's strong revenue growth reported in its Q1 2025 results. Woo indicated that the commercialization of RenovoCath and anticipated positive clinical data in Q3 will serve as strong catalysts for the stock. A clinical researcher in a lab examining a new biopharmaceutical product. The Q1 result includes ~$200K in revenue from commercial sales of RenovoCath alone. RenovoCath is an FDA-cleared and dual-balloon catheter device for the targeted isolation of blood flow and delivery of fluids. R&D expenses increased to $1.7 million, up from $1.3 million in Q1 2024, which was driven by higher employee compensation and manufacturing costs during the quarter. The company's Phase 3 TIGeR-PaC clinical trial showed promising results, with patients experiencing a median overall survival of 16 months using their targeted approach compared to 10 months with standard chemotherapy. There was also a 65% reduction in adverse events like nausea and fatigue. This trial is evaluating the company's proprietary TAMP therapy platform for the treatment of Locally Advanced Pancreatic Cancer. RenovoRx Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company that develops targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. While we acknowledge the potential of RNXT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
3 days ago
- Business
- Business Insider
Ascendiant Reaffirms Their Buy Rating on Atossa Therapeutics (ATOS)
In a report released today, Edward Woo from Ascendiant maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report), with a price target of $7.50. The company's shares opened today at $0.87. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Woo covers the Healthcare sector, focusing on stocks such as GRI Bio, Envoy Medical, and Cingulate Inc. According to TipRanks, Woo has an average return of -8.2% and a 34.36% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atossa Therapeutics with a $5.56 average price target, a 539.08% upside from current levels. In a report released today, Craig-Hallum also initiated coverage with a Buy rating on the stock with a $4.00 price target.
Business Insider
3 days ago
- Business
- Business Insider
Knightscope Inc Class A (KSCP) Receives a Buy from Ascendiant
Ascendiant analyst Edward Woo maintained a Buy rating on Knightscope Inc Class A (KSCP – Research Report) today and set a price target of $26.00. The company's shares opened today at $6.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Woo is an analyst with an average return of -8.2% and a 34.36% success rate. Woo covers the Healthcare sector, focusing on stocks such as GRI Bio, Envoy Medical, and Cingulate Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knightscope Inc Class A with a $17.00 average price target. KSCP market cap is currently $41.82M and has a P/E ratio of -0.54.
